Applications of Actigraphy

By Barry T. Peterson, PhD, Sr. Mgr., Philips Respironics Clinical Affairs

About actigraphy

Actigraphy is the measurement of motion to monitor daily activity and sleep patterns and is usually performed with miniature accelerometers. An actigraphy device is typically worn for several days or weeks on a person's wrist or hip. Motion patterns may be displayed as an actogram that shows daily activity and rest periods. The motion data can be analyzed to provide a variety of objective endpoints about circadian patterns, the level of activity, and nighttime movements. Actigraphy has been used in multiple studies on various disease states.


Value of actigraphy data in studies of Alzheimer's disease

Alzheimer's disease is a cognitive impairment, but it can manifest itself in many detrimental ways. These include alterations in daytime activity levels, sleep quality, and awake/sleep patterns. These effects of the disease are often the aspects that are most disturbing to the caregivers⁴ and are therefore reasonable endpoints for testing the efficacy of therapies³. For example, Mahlberg et al. used actigraphy to show a decrease in daytime activity in response to a therapy designed to reduce agitation⁶.

Activity and sleep can also be markers for cognitive symptoms. Zeitzer et al. showed that patient apathy was highly correlated with a specific daytime activity pattern that was independent of depression⁷. Carvalho-Bos used actigraphy to show that the instability of the patient's daily awake/sleep rhythm was related to cognitive decline², and Buchman et al. showed that the level of activity was associated with the onset of Alzheimer's disease in a four-year prospective study of 716 older subjects¹.

Published actigraphy endpoints

Total daily activity level^{1,5,6} Functional principal component analysis⁷ Circadian pattern stability^{2,3} Total sleep time, wake after sleep onset⁴



References

- Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 2012; 78:1323-1329.
- 2 Carvalho-Bos SS, Riemersma-van der Lek R, Waterhouse J, Reilly T, Van Someren EJW. Strong association of the rest-activity rhythm with wellbeing in demented elderly women. Am J Geriatr Psychiatry 2007; 15: 92-100.
- 3 David R, Mulin E, Mallea P, Robert PH. Measurement of neuropsychiatric symptoms in clinical trials targeting Alzheimer's Disease and related disorders. Pharmaceuticals 2010; 3: 2387-2397.
- 4 Friedman L, Spira AP, Hernandez B, Mather C, Sheikh J, Ancoli-Israel S, Yesavage JA, Zeitzer JM. Brief morning light treatment for sleep/wake disturbances in older memory-impaired individuals and their caregivers. Sleep Medicine 2012; 13:546-549
- 5 Galik EM, Resnick B, Gruber-Baldini A, Nahm E, Pearson K, Pretzer-Aboff I. Pilot testing of the restorative care intervention for the cognitively impaired. J.Am. Med Dir. Assoc 2008; 9: 516-522.
- 6 Mahlberg R, Walther S, Eichmann U, Tracik F, Kunz D. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: A placebo-controlled pilot study. Arch Geront Geriatrics. 2007; 45: 19-26.
- 7 Zeitzer JM, David R, Friedman L, Mulin E, Garcia R, Wang J, Yesavage JA, Robert PH, Shannon W. Phenotyping apathy in individuals with Alzheimer's disease using functional principal component analysis. Am. J. Geriatr Psychiatry 2013; 21: 391-397.

Visit: www.actigraphy.com

©2014 Koninklijke Philips N.V. All rights are reserved.

Philips Healthcare reserves the right to make changes in specifications and/or to discontinue any product at any time without notice or obligation and will not be liable for any consequences resulting from the use of this publication.

edoc SB 10/8/14 MCI 4106471

Customer Service +1 541 598 3800 Toll free, US and Canada only +1 800 685 2999 Email us: minimitter@respironics@philips.com

PHILIPS

